 BOSTON--BUSINESS WIRE--AVEO Oncology Nasdaq: AVEO today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA tivozanib in combination with OPDIVO nivolumab, Bristol Myers Squibbs anti-PD-1 therapy, in the pivotal Phase 3 TiNivo-2 trial in patients with advanced relapsed or refractory renal cell carcinoma RCC following prior immunotherapy exposure. FOTIVDA is an oral, next-generation vascular endothelial 